

Zutphen, The Netherlands, 11 November 2010

Cryo-Save Group N.V.

Operating profit up 80% and number of combined cord samples stored up 267%

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), Europe's leading adult stem cell storage bank, announces its trading update for the quarter ended 30 September 2010.

Highlights for the period were:

- Third quarter revenue of €9.6 million (Q3 2009: €9.7 million). For the period to 30 September 2010, revenue was up 3% to €29.1 million (30 September 2009: €28.4 million)
- EBITA* up 47% to €1.1 million (Q3 2009: €0.7 million). For the period to 30 September 2010, EBITA was up 29% to €3.6 million (30 September 2009: €2.7 million)
- Operating profit up 80% to €0.7 million (Q3 2009: €0.4 million). For the period to 30 September 2010, operating profit was up 42% to €2.6 million (30 September 2009: €1.8 million)
- Number of new cord tissue samples stored up 267% to 3,200 (Q3 2009: 900 samples). Over 60% of new customers opted for the combined service of cord blood and cord tissue storage, where it is available
- Volume growth of 6,200 samples (Q3 2009: 7,300). At 30 September 2010, the total number of samples stored was over 141,000
- Further roll out of new product Cryo-Lip[®], which allows collection, processing and storage of adult stem cells from fatty tissue. Doctors in Italy, Spain, Greece, Cyprus, Bulgaria and Hungary have been trained and certified to offer this service, and the first samples of Cryo-Lip[®] have now been processed and stored in the Group's facility in Belgium

*EBITA is defined as Earnings Before Interest, Taxation and Amortisation of identified intangible assets.

Highlights after 30 September 2010 were:

- Cryo-Save celebrated the first anniversary of its NYSE Euronext Amsterdam listing on 1 November 2010 by participating in the market opening ceremony
- On 3 November 2010, Cryo-Save announced the acquisition of its Bulgarian distributor, Tissue Bank Cryo Center Bulgaria AD, the leading company for stem cell banking in Bulgaria, strengthening the Group's leading position in Eastern Europe, one of its fastest growing markets

Arnoud van Tulder, Chief Executive officer, commented:

"These strong results are very pleasing and demonstrate the resilience of our business model under the challenging economic circumstances, especially within our key markets in southern Europe.

Focus on customers, costs and cash remains a key discipline for us, and we saw a modest improvement in the European economy in September and October, which gives us confidence for the near future."

Enquiries:

Cryo-Save Group

Arnoud van Tulder, Chief Executive Officer

+ 31 (0) 575 548 998

SPJ Financiële Communicatie (The Netherlands)

Kees Jongsmā/Leon Melens

+31 (0)20 6478181

Daniel Stewart & Company plc (UK)

Chris Theis

+ 44 (0) 20 7776 6550

College Hill (UK)

Rozi Morris/ Adrian Duffield

+ 44 (0) 20 7457 2020

Free footage is available on www.videobankonline.com.

About Cryo-Save

With more than 141,000 samples saved, Cryo-Save is the leading stem cell bank in Europe and one of the fastest growing in the world. Driven by its international business strategy, Cryo-Save is now represented in 40 countries on three continents with state-of-the-art processing facilities in Belgium, Germany, Dubai, India and France.